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Abstract
Human influenza A viruses (IAVs) cause global pandemics and epidemics, which remains
a nonignorable serious concern for public health worldwide. To combat the surge of viral
outbreaks, new treatments are urgently needed. Here, we design a new vaccine based on
virus‐like particles (VLPs) and show how intranasal administration of this vaccine triggers
protective immunity, which can be exploited for the development of new therapies.
H1N1 VLPs were produced in baculovirus vectors and were injected into BALB/c mice
by the intramuscular (IM) or intranasal (IN) route. We found that there were significantly
higher inflammatory cell and lymphocyte concentrations in bronchoalveolar lavage
samples and the lungs of IN immunized mice; however, the IM group had little signs of
inflammatory responses. On the basis of our results, immunization with H1N1 influenza
VLP elicited a strong T cell immunity in BALB/c mice. Despite T cell immunity
amplification after both IN and IM vaccination methods in mice, IN‐induced T cell
responses were significantly more intense than IM‐induced responses, and this was likely
related to an increased number of both CD11bhigh and CD103+ dendritic cells in mice
lungs after IN administration of VLP. Furthermore, evaluation of interleukin‐4 and
interferon gamma cytokines along with several chemokine receptors showed that VLP
vaccination via IN and IM routes leads to a greater CD4+ Th1 and Th2 response,
respectively. Our findings indicated that VLPs represent a potential strategy for the
development of an effective influenza vaccine; however, employing relevant routes for
vaccination can be another important part of the universal influenza vaccine puzzle.
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1 | INTRODUCTION
Influenza viruses are responsible for global epidemics, causing 500 million
infections—particularly in high‐risk groups, such as the elderly—and
between 250,000 and 500,000 deaths each year (Esghaei et al., 2018;
Keshavarz, Dianat‐Moghadam et al., 2018; Keshavarz, Tavakoli, Mozaffari
Nejad, Mokhtari‐Azad, & Rezaei, 2018; Shim, Kim, Tenson, Min, & Kainov,
2017). Currently, vaccination represents the most proficient strategy to
prevent seasonal or pandemic influenza outbreaks (Control, C. f. D., &
Prevention, 2013). Because seasonal vaccine requires annual reformula-
tion on the basis of experiential predictions about the circulating virus
strains in the coming year, it is essential to develop an effective influenza
vaccine with a broad coverage against different strains and also for rapid
production on a large scale with a low production cost (Fineberg, 2014).
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Influenza virus-like particles (VLPs) are a new class of recombinant
particulate vaccines comprised of hemagglutinin (HA), neuraminidase,
matrix (M1), and ion channel (M2) proteins, which have been shown to
produce bulk, safe, and low‐cost influenza virus vaccines (Keshavarz, Mir-
zaei et al., 2018; Pushko et al., 2016; Wei et al., 2011). Because these
vaccine platforms lack viral genome, they are considered attractive
candidates for immunization in the elderly and young populations, groups
that are at the highest risk of influenza complications (Quan et al., 2013).
Influenza VLPs have many advantages because of their special structure,
which is well uptaken and presented by the antigen‐presenting cells and
stimulate both effector and memory immune responses, it also has the
ability to be used through an intramuscular (IM) and intranasal (IN)
routes (Makarkov et al., 2017). Immunization with VLP through different
routes, such as IN, IM, and parenteral, induces various aspects of adaptive
and cellular immune responses (Perrone et al., 2009; Ren et al., 2018).
VLP mucosal vaccination induces both local and systemic immunity,
although the presence of appropriate adjuvants may lead to stronger
immune responses (Malm, Tamminen, Vesikari, & Blazevic, 2015).
Seasonal influenza A virus initially shows tropism to the upper
respiratory tract, whereas zoonotic viruses cause severe illness in the
lower respiratory tract (Pizzolla et al., 2017) therefore IN immunization
has an attractive route for defense against this pathogen (Luo
et al., 2018).
Lung dendritic cells (LDCs) play a pivotal role in capturing and
presenting antigens and thereby trigger immune responses. There are
two subtypes of these cells in lung, which are capable of developing
Th1 and Th2 responses, including CD103 and CD11b (Condon, Sawyer,
Fenton, & Riches, 2011). When VLPs are delivered through the IN
route, they are captured by LDCs and present via major histocompat-
ibility complex (MHC) molecules to T cells. After the activation of LDCs,
cytokines release and promote the expansion of CD8 and CD4 T cells
(Si, Wen, Kelly, Chong, & Collier, 2018). The aim of this study was to
assess the effect of H1N1 VLPs through muscular and intranasal
immunization on lung dendritic cells (DCs) and on the major cytokines
and chemokines that are inducted by Th1 and Th2 in mouse animal
models.
2 | MATERIALS AND METHODS
2.1 | VLP production, purification, and
characterization
H1N1 (PR8) VLPs containing H1, N1, and M1 were produced by using
the recombinant baculoviruses (rBV) expression system by Rezaei
et al. (Nadmdari, Keshavarz, Mokhtari‐Azad, & Rezaei, 2017; Rezaei
et al., 2013) and characterized by western blot and electron
microscopy. For VLP verification, we used sodium dodecyl sulfate
(SDS) 10–15% polyacrylamide gel and western blot analysis. For this,
3–5 ug of the purified VLP was loaded into the gel and was separated
by SDS‐ polyacrylamide gel electrophoresis and electrotransferred to a
nitrocellulose membrane (Bio‐Rad, CA). Subsequently, the membrane
was blocked with 5% skim milk overnight at 4°C and then incubated by
the primary H1, N1, and M1 mouse IgG mAbs (1:1,000 v/v) (Abcam,
Cambridge, MA). After washing with Tris‐buffered saline containing
0.1% Tween 20, the membrane was incubated with an HRP‐
conjugated secondary antibody (1:10,000 v/v) (Sigma-Aldrich, St.
Louis, MO) for 2 hr at room temperature. Also for transmission
electron microscopy, VLP specimens were adsorbed to the surface of
carbon parlodion‐coated copper grids (400 mesh) and stained with 1%
phosphotungstic acid. The images of influenza VLP were recorded with
a ZEISS EM900 transmission electron microscope at 80 kV with 85 kX
magnification.
2.2 | Immunization
Female BALB/c mice, aged 6–8 weeks, were used in this study. A total
of 12 female BALB/c mice in each group were intranasally (IN group) or
intramuscularly (IM group) immunized with 10 ug H1N1 VLP. The
control group (Mock) received only phosphate buffered saline (PBS).
Thirty six hours after first immunization, three mice in each group were
scarified and the lungs and bronchoalveolar lavage (BAL) fluids were
collected for Haemotoxylin/Eosin (H&E) staining and cell counting,
respectively. The mice received a booster dose seven days later, and
Influenza virus‐like particles then, 5 days after the second immunization,
all mice were scarified with an intraperitoneal injection of 100mg/kg
ketamine. (All experiments were approved by and performed according
to guidelines of the Animal Care and Use Committee from the Tehran
University of Medical Sciences.)
2.3 | ELISA assay
Five days after second immunization with 10 ug H1N1 VLP, three
mouse spleens were harvested from each groups, homogenized, and
suspended in PBS. Red blood cells were lysed using Hemolytic
Solution, and 105 splenocytes were seeded on 96‐well plates. After
ex‐vivo restimulation by 4 ug/ml H1N1 VLPs for 24 hr at 37°C,
suspensions were centrifuged and supernatants were collected. The
enzyme‐linked immunosorbent assay (ELISA) method was applied to
measure cytokine responses as described by the manufacturer
instructions of the Murine ELISA Development Kit (PeproTech Kits)
to determine the amounts of interferon gamma (IFN‐γ) and
interleukin (IL)‐4 cytokines.
2.4 | Real‐time PCR
To evaluate immune biomarkers that were induced by H1N1 VLPs,
total RNA was extracted from splenocyte after ex‐vivo restimulation
(as mentioned above) using TRIzol (Invitrogen, Carlsbad, CA) and
converted to cDNA by a cDNA Reverse Transcription Kit (Applied
Biosystems, Foster city, CA). Real‐time polymerase chain reaction
(PCR) by specific primer sets and Universal PCR Master Mix System
(Applied Biosystems) was used for relative quantification of target
messenger RNA (mRNA). Table 1 indicates the primer sets for mouse
mRNA targets (CXCR3, CXCR4, CCR4, and CCR5). All primers were
designed to span exons and to avoid coamplification of genomic DNA.
Specimens were tested and analyzed using the Step One Plus
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Real‐Time PCR System (Applied Biosystems) and LinRegPCR (www.
hartfaalcentrum.nl), respectively. Ct values were normalized to
β‐actin mRNA and expressed as the fold change relative to the
mean Ct value for the control samples using the Ct method.
2.5 | Bronchoalveolar lavage cells' counting,
histology, and flow cytometry
Thirty‐six hours after the first immunization, BAL fluids were collected
from the thoracic cavity ofanesthetized anesthetized BALB/c mice by
washing the lung with 2ml of sterile cold PBS. After that, BAL fluid
was centrifuged at 300g for 10min, and pellet cells were stained with
Giemsa stain. Each slide was counted three times under optical
microscope, and the percentage of leukocytes was calculated
according to the morphological criteria. Also, from each group three
mice were scarified, and lung sections were prepared and fixed for
H&E staining as described by Baligar, Pokhrel, and Mukhopadhyay
(2016). Finally, the slides were evaluated by an optical microscope.
The efficacy of lung‐proliferated T and DC cells were determined by
flow cytometry as described (Song et al., 2011; Ghaedi et al., 2015).
Briefly, the homogenized lung tissues were treated with 100μg per ml
digestion buffer (DNase I) for 30min at 37°C and then passed through a
cell strainer (40mm, BD Diagnostics, Franklin Lakes, NJ). The remaining
single‐cell suspensions were stained with fluorescence‐conjugated anti-
bodies specific to cell phenotypes (CD4, CD8, CD103, MHCII, CD11c,
and CD11b). The lung DC cells were gated according to their sizes and
granularity defined in the forward light scatter and side light scatter plot
and sorted on the basis of their CD4/CD8, CD11c/MHCII, and CD11b/
CD103 profiles. Cell acquisition was performed with a dual‐laser flow
cytometer (Attune NxT flow cytometer, Foster City, CA), and data were
analyzed using the FlowJo software (Tree Star Inc., San Carlos, CA).
2.6 | Statistical analysis
The expression as fold change related to immune responses was
evaluated according to the Ct method. The average value and
standard deviation for the level of immune responses within the
treated and control group were calculated for comparison, and the
significance of the differences between the results from different
groups was determined by Studentʼs t test using the GraphPad Prism
software (V7.0). *: p < 0.05, **: p < 0.01, and ***: p < 0.001 were
considered statistically significant.
3 | RESULTS
3.1 | Expression and characterization of proteins
To produce VLP, the recombinant‐rBV‐expressing influenza H1, N1,
and M1 was inoculated into Sf9 cells, as described by Rezaei et al.
(2013). Three days after transfection, cell lysates were subjected to
SDS, and western blot analysis showed the presence of the H1, N1,
and M1 proteins in the cell lysate. H1, N1, and M1 proteins
expressed in Sf9 cells represented a polypeptide of approximately 63,
50, and 29 kDa, as expected (Figure 1a). In addition, the images of the
electron microscope showed pleomorphic VLPs of sizes ranging from
80 to 120 nm (Figure 1b,c).
3.2 | Cells distribution in mouse BAL fluid
To assess the immune cell mixture in the lung mucus of BALB/c mice,
BAL samples were collected from the pulmonary cavity by washing
the lungs with 2ml of sterile PBS. After centrifugation at 300 g for
10min, Giemsa staining was used to evaluate the pellet cells. By
counting the stained slides, we found a significantly higher
abundance of lymphocytes in BAL fluid of IN immunized mice than
IM and mock groups (Figure 2a). The concentration of monocytes
also was significantly greater in the BAL samples of IN immunized
mice (Figure 2b). Similarly, a number of infiltrated neutrophils
showed a significant increase in the BAL samples of IN immunized
mice (Figure 2c). Overall, the BAL samples of IN vaccinated mice had
a significantly greater total immune cell content than the two other
groups (Figure 2d). These data suggest a remarkable inflammatory
and lymphocyte response in lung mucus after immunization through
the IN route.
3.3 | Chemokine receptor expression
We evaluated the chemokine receptor expression in the harvested
spleens from IN or IM vaccinated and nonvaccinated mice. After RNA
extraction from the lysates of spleen cells and cDNA synthesis, the
mRNA expression level of four chemokine receptors was measured
by real‐time PCR using specific primer sets. The results of real‐time
PCR showed that after IN VLP immunization, CXCR3 and CCR5
chemokine receptors of T cells had a significantly higher mRNA
expression level than those in the IM or mock groups. On the other
hand, contrary to those in the IN and the mock groups, the mRNA
expression levels of CXCR4 and CCR4 chemokine receptors were
significantly higher in the IM group (Figure 3).
TABLE 1 Primer sequences of target genes and reference gene
used for relative quantitative Real‐Time PCR











Note. PCR: polymerase chain reaction.
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3.4 | Cytokine responses
Then, we compared the cytokine response of splenocytes obtained
from each group of vaccinated and nonvaccinated mice in this study.
After ex‐vivo restimulation of splenocytes with the same VLP, the
ELISA method was utilized to measure the quantity of IFN‐γ and IL‐4
cytokines in the supernatants collected from splenocytes suspensions.
On the basis of the data of this section, IN immunization led to a
significant increase of the IFN‐γ level in splenocytes (Figure 4a). In
terms of IL‐4, although IM immunization induced a higher IL‐4 response
than IN immunization, it was not significant. However, the level of IL‐4
in both IM and IN groups had a significant increase compared with the
mock group (Figure 4b). These results were indicative of almost
opposite cytokine response patterns in IN and IM immunized mice.
3.5 | Lung immune cell responses and variation
To determine the rate of immune cell recruitment in lungs after
immunization, we examined the lung tissue sections of mice. After
sacrificing the mice, lungs were harvested and sections were prepared,
fixed, and finally stained with H&E to be evaluated under an optical
microscope. We observed a high frequency of lung‐tissue‐infiltrating
immune cells in the IN immunized group (Figure 5a). On the other
hand, the lung sections of the IM immunized group (Figure 5b) and the
mock group (Figure 5c) had no evident infiltration of immune cells. The
results obtained from the IN group in this part indicated an intense
concentration of immune cells in lung tissues in response to mucosal
immunization and were consistent with the results of the cell
distribution in BAL samples.
3.6 | T cell and dendritic cell responses
The homogenized lung samples were treated with digestion buffer.
Single‐cell suspensions were stained with fluorescence‐conjugated
antibodies specific to cell phenotypes. The lung DC cells were gated
according to their sizes and granularity and sorted on the basis of their
CD4/CD8, CD11c/MHCII, and CD11b/CD103 profiles. Cell acquisition
was performed with a dual‐laser flow cytometer, and data were analyzed
using the FlowJo software. According to our data, after IN administration
of VLP, there is a significant increase in the number of both CD11bhigh
and CD103+ DCs in lung samples, whereas after receiving IM VLP or
PBS (mock), the population of DCs showed no significant changes. Our
findings also demonstrated that there is a significant increase in CD4+
and CD8+ cellular responses in IN‐VLP‐immunized mice in comparison
with IM vaccinated and control groups (Figure 6).
4 | DISCUSSION
In the present study, we investigated the efficacy of T‐cell immune
responses after IN or IM administration of influenza VLP vaccines in
BALB/c mice and compared the immune response patterns after
immunization through the mentioned routes. The H1N1 VLP vaccine
utilized in this study was developed by using a recombinant
baculovirus‐based expression of H1, N1, and M1 proteins in the Sf9
cell line, which has been proved to be a safe, high‐yield, and low‐cost
vaccine production method (Bright et al., 2008). It has been shown that
VLPs, as new vaccine candidates, can be produced with a high yield in a
short time period and are also promising platforms to enhance the
F IGURE 1 Characterization of influenza H1N1 VLP. Western blot analysis of H1N1 VLP produced in sf9 cells with anti‐H1, N1, and M1
Mabs, Sf9 cell, and H1N1 virus were used as negative and positive control, respectively. The molecular weight of H1, N1, and M1 proteins were
63, 50, and 29 KDa, respectively (a). Negative staining with 1% phosphotungstic acid and transmission electron microscopy shows influenza
VLPs (b,c). Bar represents 300 and 100 nm, respectively. VLP: virus‐like particle [Color figure can be viewed at wileyonlinelibrary.com]
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immunogenicity of antigens (Bright et al., 2007; Fries, Smith, & Glenn,
2013; Hossain et al., 2011; Wang et al., 2012). Because of their
multivalent particulate structure, VLPs can be taken up and processed
by dendritic cells (DCs) more efficiently and, thereupon, can strongly
provoke effector humoral and cellular immune responses, making them
more immunogenic than other vaccine types (Chackerian, Lenz, Lowy,
& Schiller, 2002; Harper et al., 2006; Haynes, 2009; Lenz et al., 2001;
Lenz et al., 2003; Song et al., 2010). In addition, VLPs are safer vaccine
products compared with the former traditional live attenuated or
inactivated vaccines (Roldão, Mellado, Castilho, Carrondo, & Alves,
2010). Despite many advantages, VLP vaccines produced on the basis
of insect cells are also (Sf9) subject to certain restrictions. One of the
important attributes of these cells is contamination with baculovirus
particles (similar densities with influenza VLP) or baculovirus DNA.
Indeed, this contamination induces immune responses and produces
unwanted cytokines responses. On the other hand, production and
purification of some VLPs may represent a limitation, especially for
enveloped recombinant virus‐like particles (rVLPs; Margine, Martinez‐
Gil, Chou, & Krammer, 2012; Pitoiset, Vazquez, & Bellier, 2015).
The VLP vaccine described in this study also showed considerable
immunogenicity and stimulated protective cellular immune responses
as well.
A growing body of evidence emphasizes the determinative effect
of administration route on the immunization outcome. A majority of
the current research on VLP administration ahs focused their work
on IN and IM routes (Hodgins et al., 2017; Price, Lo, Misplon, &
Epstein, 2018; Ren et al., 2018; Trondsen et al., 2015), although other
ways, such as the intradermal route, are under investigation (Quan
et al., 2010). A critical requirement for comparing these routes
usually includes a magnitude of stimulated inflammatory as well as
protective immune responses. Here, we evaluated some immunolo-
gical aspects of IN and IM immunization of mice by VLPs.
F IGURE 2 The distribution of immune
cells in BAL fluid of mice immunized IM and
IN with H1N1 VLP. Immune cells were
collected from BAL fluid 36 hr post
immunization. The numbers of lymphocytes
(Lym; a), monocytes (Mon; b), neutrophils
(Neu; c), and total cell content (d) were
analyzed in the BAL fluid. A remarkable
inflammatory and lymphocyte response in
lung mucus after immunization through the
IN route (a–d). (*p<0.05, **p < 0.01,
***p<0.001). BAL: bronchoalveolar
lavage; IM: intramuscular; IN: intranasal
F IGURE 3 mRNA expression levels of four chemokine receptor
genes in splenocytes after ex‐vivo restimulation by 4 ug/mlH1N1
VLPs. CXCR3 and CCR5 chemokine receptors of T cells had a
significantly higher mRNA expression level in the IN group, whereas
CXCR4 and CCR4 showed an increase in IM immunized mice.
(**p < 0.01, ***p < 0.001). IN: intranasal; mRNA: messenger RNA;
VLP: virus‐like particle
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IN immunization with VLPs can alter the immune cell content of
lung mucus and density of cell infiltration within the lung tissue in
mice (Ren et al., 2018). Our results imply a significantly higher
concentration of inflammatory cells (i.e. monocytes and neutrophils)
and lymphocytes in the BAL samples of IN vaccinated mice compared
with IM and mock groups. In the same way, we found a large number
of infiltrated immune cells in the lung tissues of IN immunized mice,
but there were no signs of accumulation of immune cells in the lungs
of IM immunized or mock groups. The plain reason for these
increased cellular and inflammatory responses in BAL and lung, in
addition to mucosal stimulation provided via the IN route, is probably
the partial imitation of the immune response pattern of influenza
infection by the VLPs. According to our survey, VLP administration
can induce an almost considerable inflammatory response. However,
as shown recently, immunizing mice with VLPs before influenza
infection leads to a significant decrease in inflammatory cells in BAL
and lungs compared with nonimmunized, influenza‐infected mice
(Kim et al., 2015; Lee et al., 2016; Lee et al., 2018).
As mentioned above, VLPs can be taken up by DCs more
efficiently, leading to a stronger immune response. Sung et al. (2006)
have reported that mouse LDCs possess two major subsets, including
CD11c+ MHC class II+ CD11 blow or negative CD103+ LDCs (CD103+
LDCs) and CD11c+ MHC class II+ CD11bhigh CD103− LDCs (CD11bhigh
LDCs). A study highlights that mice CD103+ LDCs induce proliferation
of CD4+ T cells expressing higher levels of IFN‐γ and also CXCR3 and
CCR5 chemokine receptors, indicating a dominant Th1 response,
whereas induction by CD11bhigh LDCs mediates proliferation of CD4+
T cells expressing higher levels of IL‐4, CXCR4, and CCR4, exhibiting a
greater Th2 response (Furuhashi et al., 2012). According to our data,
after IN administration of VLP, a significant increase occurred in the
number of both CD11bhigh and CD103+ DCs in mice lung, whereas
after receiving IM VLP, the population of DCs showed no significant
change. Because CD11bhigh and CD103+ DCs are lung‐resident cells,
IN vaccination as a principal stimulant of mucosal immunity, raises the
frequency of both DCs in mice lungs, and this fact can be indicative of
a propensity toward approximately balanced Th1 and Th2 cellular
responses. This was after IN VLP immunization, CXCR3 and CCR5
chemokine receptors of CD4+ T cells in spleens had a higher mRNA
expression level than those in IM or mock groups; however, the
CXCR4 and CCR4 expression levels were higher in the IM group than
IN and mock groups, representing greater CD4+ Th1 and Th2
responses after IN and IM immunization with VLP, respectively.
F IGURE 4 The concentration of two cytokines produced by splenocytes after ex vivo stimulation. Five days after the second immunization,
splenocytes were collected and stimulated ex vivo for 24 hr with 4 ug/ml H1N1 VLP. Concentrations of IFN‐γ (a) and IL‐4 cytokines (b) in the
supernatant were measured by ELISA. There were two different cytokine response patterns after IN and IM immunization. (a,b). (**p < 0.01,
***p < 0.001). ELISA: enzyme‐linked immunosorbent assay; IFN‐γ: interferon; IL: interleukin; IM: intramuscular; IN: intranasal; mRNA: messenger
RNA; VLP: virus‐like particle
F IGURE 5 The lungs were removed from BALB/c mice 36 hr after immunization with H1N1 VLPs. (a) The lungs had increased cell population as
triggered by the infiltration of immune cells and triggered the APC process in the IN route. (b,c) The lung tissue from IM immunized and control
groups (Mock) did not show significant cells infiltration. H&E staining colors cytoplasm pink and nuclei blue. APC: antigen‐presenting cell;
IM: intramuscular; IN: intranasal; H&E: hemotoxylin and eosin; VLP: virus‐like particle [Color figure can be viewed at wileyonlinelibrary.com]
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Similarly, we showed that IN immunization leads to a considerable
increase in the IFN‐γ level in splenocytes, indicating a significant trend
toward CD4+ Th1 response, which was comparable with the
chemokine receptor results. Although IL‐4 production induced by IM
immunization was slightly higher compared with that of IN immuniza-
tion—which suggests a somewhat higher Th2 response—the difference
was not significant. Several other studies also have emphasized that
measuring cytokine and chemokine levels in spleen and lung can be
very helpful in determining the type and efficacy of immune responses
after immunization and have shown that different cytokine responses
can be caused by immunization from IN or IM routes (Hodgins et al.,
2017; Hu et al., 2017; Kim et al., 2013; Trondsen et al., 2015). In a
study of Hodgins et al. (2017), the levels of Th1‐inducing cytokines
were higher in the spleens of IN immunized mice, but the IM
immunized ones had greater levels of Th2‐related cytokines. Another
survey by VLPs expressed that more quantities of IFN‐γwere detected
in the splenocytes of IN vaccinated mice, but the levels of IL‐4 were
almost equal in both IM and IN immunized sets. Also, Trondsen et al.
(2015) reported results similar to our study in terms of Th1 and Th2
specific cytokines by using another vaccine platform.
On the basis of the available evidence, CD4+ and CD8+ T cells
have an undeniable role in recovery from influenza infection (Lee
et al., 2018), and interestingly, after influenza VLP immunization, a
remarkable increase occurs in cross‐reactive poly‐functional T cell
populations in lungs (Landry et al., 2014). On the basis of previous
studies, different vaccine administration routes have various
activation results in terms of T cell responses (Hemann, Kang, &
Legge, 2013; Landry et al., 2014; Pillet et al., 2016; Sung et al.,
2006). By comparing the studied groups, we demonstrated that
contrary to IM immunized or control groups, IN VLP immunized
mice develop significantly more intense CD4+ and CD8+ cellular
responses in the lungs. Regarding the presence of high frequencies
of specific DCs in lungs, such increases in the population of T cells
are explainable and can be confirmed by obvious infiltration of
lymphocytes in BAL and lung sections. Ren et al. (2018) reported
that although IM vaccination by H7N9 VLPs causes elevated levels
of the lung, existing CD4+ and CD8+ memory cells, VLPs
administered IN, inducing a stronger response of this type. In a
former study on whole inactivated influenza virus vaccine, CD4+
cells with various functionalities were detected in higher numbers
in the IN than IM immunized group of mice (Trondsen et al., 2015).
During a clinical trial study, IM injection of H1 and H5 VLP
vaccines provoked greater polyfunctional CD4+ and CD8+ T‐cell
responses than trivalent inactivated vaccine and placebo, which
F IGURE 6 The percentage of T cells and dendritic cells in lung tissue. IN immunized mice induced CD103+ and CD11b+ DCs in the lungs
(a–e). Percentage of CD11b+ and CD103+ DC populations gated from CD11c+ MHCII+. Significant induction of CD4+ and CD8+ cells in the lung
was seen in the IN group than IM immunized or control groups (a–e). (**p < 0.01). DC: dendritic cell; IM: intramuscular; IN: intranasal [Color
figure can be viewed at wileyonlinelibrary.com]
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were durable for more than 6 months (Landry et al., 2014). Also, as
Hemann et al. (2013) demonstrated, IN vaccination with influenza
VLPs leads to a considerable increase in HA‐specific CD8 T cells in
mice lungs. In light of what is explained here, vaccination with VLP
can be an effective factor in limiting and clearing the infection in
the lungs through enhancing the response of various T‐cell lines.
Of course, as discussed above, lung habitant DCs play an essential
role in triggering such functional T cell responses.
5 | CONCLUSION
We have shown that immunization with H1N1 influenza VLP elicits
a strong and protective T cell immunity in BALB/c mice. We also
demonstrated that vaccination from both IN and IM routes leads
to augmenting T‐cell immunity in mice however, IN induced T‐cell
responses were significantly more extensive than those induced
through the IM route, which was probably because of the
increased frequency of CD103+ and CD11bhigh DCs in the lungs.
On the other hand, IN vaccination led to a CD4+ T‐cell response
trend towards Th1, whereas a greater Th2 response was
motivated via IM route. These data suggest that VLPs could be
introduced as stimulators of cellular and humoral immune
responses in comparison with their previous counterparts, which,
along with better safety profile reported in other studies, can
reflect the clear superiority of VLP vaccines. Moreover, this study
characterized the IN route as a more advantageous vaccination
method. Taken together, the results of this study, as well as other
similar studies, illustrate that selecting an appropriate route for
vaccination is an effective factor on immunization result. Accord-
ingly, more comparative preclinical and clinical surveys are needed
to specify the most reasonable route or a combination of routes
for VLP vaccine administration in humans.
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